Codon-Optimized AAV Vectors for Sustained Factor VIII Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A, such as Factor VIII replacement therapy, are costly, require frequent administration, and can lead to the formation of anti-Factor VIII inhibitor antibodies, while gene therapy faces challenges in immunogenicity and expression efficiency.
Innovation Solution
The use of codon-optimized adeno-associated virus (AAV) vectors to deliver a Factor VIII polypeptide with specific amino acid substitutions and a liver-specific promoter, enhancing expression and reducing immunogenicity, with the nucleic acid sequences optimized for high potency and integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Factor VIII replacement therapy is administered, then Factor VIII activity is restored, but treatment cost increases and frequency of administration increases
Solution Approach 1:
The patient's own liver cells are engineered to produce Factor VIII endogenously through AAV-mediated gene delivery, eliminating the need for external replacement therapy. The transduced hepatocytes continuously express functional FVIII, creating a self-sustaining therapeutic effect that does not require repeated administrations.
Solution Approach 2:
A single preliminary gene therapy administration establishes long-term Factor VIII production capacity before clinical need arises. The codon-optimized transgene is integrated into hepatic DNA, preparing the system for sustained endogenous expression that replaces the need for ongoing exogenous therapy.
2Reliability
If Factor VIII replacement therapy is used, then coagulation function is improved, but immune response increases due to inhibitor antibody formation
Solution Approach 1:
The nucleotide sequence of the FVIII gene is codon-optimized to match human hepatic codon usage preferences. This parameter change in the genetic sequence enhances translation efficiency and protein expression while reducing immunogenicity, as the resulting protein is produced by the patient's own cells rather than introduced as foreign protein.
Solution Approach 2:
The patient's liver cells produce the therapeutic Factor VIII through endogenous gene expression, making the protein self-generated rather than externally administered. This eliminates the immune system's recognition of foreign protein structures, preventing inhibitor antibody formation while maintaining coagulation function.
3Productivity
If viral vectors are used for gene therapy, then Factor VIII expression is achieved, but safety concerns arise due to immune responses to the vector
Solution Approach 1:
The FVIII gene is codon-optimized with nucleotide sequences tailored to human hepatic codon bias. This parameter optimization enhances translational efficiency in liver cells while the resulting protein's native structure and post-translational modifications reduce immunogenicity compared to non-optimized or heterologous expressions.
Solution Approach 2:
The AAV vector serves as a benign intermediary that delivers the codon-optimized FVIII transgene to hepatic nuclei without itself being the therapeutic agent. The vector's non-integrating, non-pathogenic nature provides safe gene delivery, while the codon-optimized transgene ensures efficient, low-immunogenicity protein production.
Data Source
AI summary
Disclosed herein are codon-optimized nucleic acids encoding a Factor VIII polypeptide. Also disclosed are expression cassettes and expression vectors (e.g., recombinant AAV (rAAV) vectors) that contain the codon-optimized nucleic acids in expressible form. Methods for the treatment of Hemophilia A comprising administering expression vector comprising the codon-optimized nucleic acids (e.g., a recombinant AAV (rAAV) vector) are also disclosed.